Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Identification of novel serological biomarkers for inflammatory bowel disease using Escherichia coli proteome chip.

Chen CS, Sullivan S, Anderson T, Tan AC, Alex PJ, Brant SR, Cuffari C, Bayless TM, Talor MV, Burek CL, Wang H, Li R, Datta LW, Wu Y, Winslow RL, Zhu H, Li X.

Mol Cell Proteomics. 2009 Aug;8(8):1765-76. doi: 10.1074/mcp.M800593-MCP200.

2.

Low Mass Blood Peptides Discriminative of Inflammatory Bowel Disease (IBD) Severity: A Quantitative Proteomic Perspective.

Wasinger VC, Yau Y, Duo X, Zeng M, Campbell B, Shin S, Luber R, Redmond D, Leong RW.

Mol Cell Proteomics. 2016 Jan;15(1):256-65. doi: 10.1074/mcp.M115.055095.

3.

Fragments of Citrullinated and MMP-degraded Vimentin and MMP-degraded Type III Collagen Are Novel Serological Biomarkers to Differentiate Crohn's Disease from Ulcerative Colitis.

Mortensen JH, Godskesen LE, Jensen MD, Van Haaften WT, Klinge LG, Olinga P, Dijkstra G, Kjeldsen J, Karsdal MA, Bay-Jensen AC, Krag A.

J Crohns Colitis. 2015 Oct;9(10):863-72. doi: 10.1093/ecco-jcc/jjv123.

PMID:
26188349
4.

Quantification and characterization of mucosa-associated and intracellular Escherichia coli in inflammatory bowel disease.

Elliott TR, Hudspith BN, Wu G, Cooley M, Parkes G, Quiñones B, Randall L, Mandrell RE, Fagerquist CK, Brostoff J, Rayment NB, Boussioutas A, Petrovska L, Sanderson JD.

Inflamm Bowel Dis. 2013 Oct;19(11):2326-38. doi: 10.1097/MIB.0b013e3182a38a92.

PMID:
23989750
5.

Novel, objective, multivariate biomarkers composed of plasma amino acid profiles for the diagnosis and assessment of inflammatory bowel disease.

Hisamatsu T, Okamoto S, Hashimoto M, Muramatsu T, Andou A, Uo M, Kitazume MT, Matsuoka K, Yajima T, Inoue N, Kanai T, Ogata H, Iwao Y, Yamakado M, Sakai R, Ono N, Ando T, Suzuki M, Hibi T.

PLoS One. 2012;7(1):e31131. doi: 10.1371/journal.pone.0031131.

6.
7.

Seroreactivity to E. coli outer membrane protein C antibodies in active inflammatory bowel disease; diagnostic value and correlation with phylogroup B2 E. coli infection.

Petersen AM, Schou C, Mirsepasi H, Engberg J, Friis-Møller A, Nordgaard-Lassen I, Wildt S, Krogfelt KA.

Scand J Gastroenterol. 2012 Feb;47(2):155-61. doi: 10.3109/00365521.2011.639080.

PMID:
22150030
8.
9.

Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies.

Bennike T, Birkelund S, Stensballe A, Andersen V.

World J Gastroenterol. 2014 Mar 28;20(12):3231-44. doi: 10.3748/wjg.v20.i12.3231. Review.

10.

Advances in clinical laboratory tests for inflammatory bowel disease.

Nakamura RM, Matsutani M, Barry M.

Clin Chim Acta. 2003 Sep;335(1-2):9-20. Review.

PMID:
12927679
11.

Combined serological, genetic, and inflammatory markers differentiate non-IBD, Crohn's disease, and ulcerative colitis patients.

Plevy S, Silverberg MS, Lockton S, Stockfisch T, Croner L, Stachelski J, Brown M, Triggs C, Chuang E, Princen F, Singh S.

Inflamm Bowel Dis. 2013 May;19(6):1139-48. doi: 10.1097/MIB.0b013e318280b19e.

12.

Association of Anti-glycan Antibodies and Inflammatory Bowel Disease Course.

Paul S, Boschetti G, Rinaudo-Gaujous M, Moreau A, Del Tedesco E, Bonneau J, Presles E, Mounsef F, Clavel L, Genin C, Flourié B, Phelip JM, Nancey S, Roblin X.

J Crohns Colitis. 2015 Jun;9(6):445-51. doi: 10.1093/ecco-jcc/jjv063.

PMID:
25895876
13.

Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease.

Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki M, Voudouri T, Kouroumalis EA.

Inflamm Bowel Dis. 2006 Feb;12(2):100-5.

PMID:
16432373
14.

Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease.

Bansi DS, Chapman RW, Fleming KA.

Eur J Gastroenterol Hepatol. 1996 Sep;8(9):881-5.

PMID:
8889455
15.

Intestinal colonization with phylogenetic group B2 Escherichia coli related to inflammatory bowel disease: a systematic review and meta-analysis.

Petersen AM, Halkjær SI, Gluud LL.

Scand J Gastroenterol. 2015;50(10):1199-207. doi: 10.3109/00365521.2015.1028993. Review.

PMID:
25910859
16.

Decreased serum fetuin-A levels and active inflammatory bowel disease.

Ma P, Feng YC.

Am J Med Sci. 2014 Jul;348(1):47-51. doi: 10.1097/MAJ.0000000000000195.

PMID:
24487480
17.

Familial and sporadic inflammatory bowel disease: comparison of clinical features and serological markers in a genetically homogeneous population.

Halme L, Turunen U, Heliö T, Paavola P, Walle T, Miettinen A, Järvinen H, Kontula K, Färkkilä M.

Scand J Gastroenterol. 2002 Jun;37(6):692-8.

PMID:
12126248
18.

Serologic testing for inflammatory bowel disease.

Hoffenberg EJ, Fidanza S, Sauaia A.

J Pediatr. 1999 Apr;134(4):447-52.

PMID:
10190919
19.

Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study.

Zissimopoulos A, Vradelis S, Konialis M, Chadolias D, Bampali A, Constantinidis T, Efremidou E, Kouklakis G.

Scand J Gastroenterol. 2014 Aug;49(8):942-9. doi: 10.3109/00365521.2014.920910.

PMID:
24897131
20.

Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype.

Seow CH, Stempak JM, Xu W, Lan H, Griffiths AM, Greenberg GR, Steinhart AH, Dotan N, Silverberg MS.

Am J Gastroenterol. 2009 Jun;104(6):1426-34. doi: 10.1038/ajg.2009.79.

PMID:
19491856

Supplemental Content

Support Center